Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.21.2
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 28, 2020
Apr. 30, 2021
Oct. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Loss Contingencies [Line Items]                
Audit committee findings           The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not.    
Payments to physicians that lack documentation of sufficient detail     $ 300,000          
Total net revenue       $ 1,005,000 $ 900,000 $ 2,123,000 $ 2,274,000  
Settlement Agreement                
Loss Contingencies [Line Items]                
Allegations description           The Settlement Agreement recites that a complaint filed by a former employee on behalf of the federal government in the United States District Court for the Eastern District of Michigan, and subsequently amended to assert claims on behalf of certain states, alleged, among other things, that the Company violated the False Claims Act, 31 U.S.C. § 3729, and certain state false claims acts by paying kickbacks to certain physicians in order to induce them to use the DABRA laser system, promoting off-label use of the DABRA laser system, failing to report adverse events to the United States Food and Drug Administration, marketing a device that does not work as advertised, and failing to adhere to Current Good Manufacturing Practices. The complaint, which was settled in connection with the Settlement Agreement, also alleged that we unlawfully retaliated against the former employee. Separate from the former employee’s allegations in the civil action, the United States and the participating states contend that from May 1, 2017 through October 31, 2019, the Company (a) paid illegal remuneration to certain physicians to induce them to use the DABRA laser system in violation of the federal anti-kickback statute and (b) marketed the DABRA laser system for off-label use in atherectomy procedures despite product performance issues causing calibration and overheating problems, which posed a risk to physicians and patients (the “Covered Conduct”). The Company denies the allegations in the civil action and those asserted by the United States and the participating states, and the settlement does not constitute an admission of liability or wrongdoing by the Company.    
Litigation settlement amount               $ 2,500,000
Payment for legal settlement   $ 100,000           $ 2,400,000
Settlement amount , year 2021 $ 500,000              
Settlement year one 2021              
Settlement amount , year 2022 $ 750,000              
Settlement year two 2022              
Settlement amount , year 2023 $ 1,000,000              
Settlement year three 2023              
Settlement amount , year 2024 $ 1,250,000              
Settlement year four 2024              
Business acquisition, settlement amount $ 5,000,000              
Business acquisition additional settlement percentage 4.00%              
Business acquisition, transaction costs $ 100,000,000              
Business acquisition change In control payments 28,000,000              
Settlement claim 56,000,000              
Settlement expense 200,000              
Loss contingency, payments 2,700,000              
Settlement Agreement | Maximum [Member]                
Loss Contingencies [Line Items]                
Total net revenue $ 10,000,000